In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in ...

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Expanding Lilly’s U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

A major pharmaceutical company is making an announcement on Tuesday regarding growth of biopharma innovation in the Rocket ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...